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SUMMARY
From June to July 1999 an outbreak of acute respiratory illness occurred in the town of Iporanga. Out of a total of 4,837
inhabitants, 324 cases were notified to the Regional Surveillance Service. Influenza virus was isolated from 57.1% of the collected
samples and 100% seroconversion to influenza A (H1N1) was obtained in 20 paired sera tested. The isolates were related to the A/
Bayern/07/95 strain (H1N1). The percentages of cases notified during the outbreak were 28.4%, 29.0%, 20.7%, 6.2% and 15.7% in
the age groups of 0-4, 5-9, 10-14, 15-19 and older than 20 years, respectively. The highest proportion of positives was observed
among children younger than 14 years and no cases were notified in people older than 65 years, none of whom had been recently
vaccinated against influenza. These findings suggest a significant vaccine protection against A/Bayern/7/95, the H1 component
included in the 1997-98 influenza vaccine for elderly people. This viral strain is antigenically and genetically related to A/Beijing/
262/95, the H1 component of the 1999 vaccine. Vaccines containing A/Beijing/262/95 (H1N1) stimulated post-immunization
hemagglutination inhibition antibodies equivalent in frequency and titre to both A/Beijing/262/95-like and A/Bayern/7/95-like viruses.
Thus, this investigation demonstrates the effectiveness of vaccination against influenza virus in the elderly.
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INTRODUCTION
Influenza is a highly contagious, acute respiratory disease and is
responsible each year for local, regional, or worldwide epidemics26.
Because of this continuing threat to Public Health, surveillance is the
only tool suitable to detect new strains and to adopt strategies to avoid
dramatic consequences of the dissemination of new strains32. No other
acute febrile disease with respiratory symptoms can spread so rapidly to
a large number of people.
Influenza virus incidence is relatively high among children and young
adults, but serious morbidity and mortality are highest among people
older than 65 years and people of any age who have medical conditions
that place them at risk for complications from influenza7.
This report describes results from a collaborative study between the
“Divisão de Vigilância Epidemiologica da DIR XVII Registro (Direção
Regional da Saúde)” and the Respiratory Virus Laboratory, Instituto
Adolfo Lutz to evaluate an outbreak of acute respiratory illness in the
town of Iporanga.
MATERIALS AND METHODS
Population - The population studied lives in the urban area of
Iporanga located in the Southeast region of Brazil. The territorial area
and population density are 1162 Km2 and 4 inhabitants/Km2, respectively.
Nearly 45.7% of the total population of 4,837 lives in the town. The
most important sectors of Iporanga’s economy are agriculture and
tourism. The climate of this region has been defined as subtropical
according to the Köppen classification11. Regarding health services,
Iporanga has primary health care, and a local hospital. In addition, family
physicians and six health care services are located in the urban and rural
area, respectively.
Collection of throat specimens and blood samples - A total of
seven throat swabs were collected during the peak of the outbreak from
patients 0 to 14 years of age with acute respiratory illness. The patients
presented fever, headache, myalgia, pharyngitis, and some of them
reported abdominal pain, nausea and vomiting after the initial symptoms.
Paired serum samples were collected from patients 0 to 12 years of age
with influenza-like illness. An acute phase specimen was collected within
five to seven days after the onset of the illness, and a convalescent phase
specimen was collected 2-3 weeks later.
Processing throat swabs for virus isolation - Swabs were removed
from the collection vial and vigorously shaked in 2.5 mL of cell culture
medium in a vortex mixer and 1000 U/mL of penicillin and 1000 g/mL
of streptomycin were added. Cell cultures of MDCK (Mardin Darby
canine), HEp-2 (human epidermoid carcinoma of the larynx), Vero
(African green monkey, kidney) were inoculated. The Hep-2 cell culture
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was maintained in Eagle’s minimal essential medium with 2% fetal calf
serum, while Vero and MDCK cell cultures were maintained in Eagle’s
minimal essential medium without serum and supplemented with 2 g/
mL trypsin. The cultures were replenished with fresh medium every 3
days and examined every other day for cytopathic effect or for the
presence of hemadsorption over a period of 14 days. The hemadsorption
test was done seven days after inoculation of clinical specimens in culture
tubes of Vero cells with guinea pig erythrocytes and of MDCK with
chicken erythrocytes. Virus isolated from cell culture was identified by
immunofluorescence with monoclonal antibodies of the respiratory Panel
1 Viral Screening & Identification Kit, (Chemicon International Inc.,
Temecula, CA). Isolated viruses were sent to the Influenza Branch at the
Centers for Disease Control and Prevention – Atlanta, GA, for further
antigenic and genetic analysis.
Immunofluorescence assay (IF) - Cells from positive cultures were
prepared for IF as described previously29. Monoclonal antibodies from
the Respiratory Panel 1 Viral Screening & Identification Kit (Influenza
A and B, Respiratory Syncytial Virus, Adenovirus and Parainfluenza
Viruses types 1, 2 and 3) from Chemicon International, Inc. (Temecula,
CA), were used as reagents for IF. Cells were harvested, washed with
sterile phosphate buffered saline PBS (pH 7.2) and resuspended in a few
drops of PBS. Two cell smears on each microscope slide were prepared
and then fixed in anhydrous acetone for 10 minutes at 4 oC. Uninfected
cells were used as control. Cells were incubated with 25 L of the
monoclonal antibodies for 30 minutes at 37 ºC. After washing with PBS,
25 L of fluorescein-conjugated antimouse IgG were added and
incubated for another 30 min. After three washes with PBS, the specimens
were examined under a fluorescent microscope. All clinical specimens
were read by two observers. Doubtful or discrepant samples were re-
stained and read at least twice to check for reproducibility.
Hemagglutination inhibition test - Sera were inactivated by heating
at 56 oC for 30 minutes and the nonspecific inhibitors of hemagglutination
were destroyed with receptor-destroying enzyme (RDE) just prior to
titration. Paired serum samples were tested by hemagglutination /
inhibition for antibodies against influenza virus A subtypes and influenza
virus type B. The strains for the studies included influenza viruses A/
Taiwan/1/86-like H1N1, A/Beijing/262/95-like H1N1, A/Wuhan/359/
95-like H3N2, A/Sydney/05/97-like H3N2, B/Guangdong/8/93, B/
Beijing/184/93 and B/Beijing/234/97 reference antigens provided by
the World Health Organization (WHO) kit and A/Bayern/07/95-like
H1N1 strains isolated during the outbreak. Hemagglutination/inhibition
for antibodies against parainfluenza virus was also performed. Titration
of hemagglutination/inhibition antibodies was performed on U- shaped
96-well microplates by a standard method with 4 units of virus and 0.5%
red blood cells20.
An indirect immunofluorescence test was done for adenovirus and
respiratory syncytial virus for the detection of antibody response as
described elsewere31.
In adddition, Elisa was performed for measles, rubella and dengue
viruses for the detection of antibody response as follows:
Measles virus – Measles virus specific IgM was tested with three
different kits: 1) Measles IgM capture Enzyme Immunoassay provided
by the Centers for Disease Control and Prevention (CDC), Atlanta,
Georgia; 2) Measles IgM capture Enzyme Immunoassay (Chemicon
International Inc, Temecula, CA); 3) EnzygnostR anti–measles virus/IgM
(Dada Behringer Gmbh, Germany), as part of the Adolfo Lutz Institute
normal routine for measles diagnosis.
Rubella virus – The assay used for the detection of Rubella virus
antibodies was the Rubenostika IgM II microelisa system (Organon
Teknika, Boxtel, NL).
Dengue virus – Mac-Elisa was carried out as described elsewere13.
Conjugated indicator antibodies and ABTS substrate (2,2-azino-di-(3
ethil benzothiazoline sulfonic acid) were obtained from Jackson Immuno
Research Laboratories and Kirkegaard & Perry Laboratories (KPL),
respectively. Anti-Human IgM was provided by Sigma; serotypes of
dengue virus type 1 and dengue virus type 2 were produced in Swiss
suckling mouse brain by the personnel of the Arthropod-borne Disease
Laboratory of Adolfo Lutz Institute.
RESULTS
During the 20 days of the oubreak, 324 people became ill, and a
higher concentration of notified cases between 06/25/99 and 07/04/99
was clearly demonstrated in (Fig. 1). Work absenteism was remarkable
and the local school was closed. Cases also occurred among health service
attendants, nurses and physicians. Only seven throat swabs were collected
because when the outbreak was detected, appropriate media for the
collection of samples were not routinely availabe at health care facilities
in Iporanga County. By the time proper collection kits were made
available, only seven samples were collected. Of seven throat swabs
submitted for virus isolation, four (57.1%) were positive for influenza
virus antigenically related to A/Bayern/07/95 (H1N1). Serological tests
demonstrated seroconversion to the influenza virus strains A/Taiwan/1/
86-like H1N1 and the homologous strains A/Bayern/07/95-like H1N1
in 100% of the samples studied. On the other hand, seroconversion against
influenza virus A/Beijing/2692-like H1N1 strains was obtained in only
one case. Among the 20 paired samples of sera studied, two mixed
infection (10%) with parainfluenza virus were detected. In addition,
mixed infection with both influenza virus subtypes H1N1 and A/Wuhan/
359/95-like H3N2 was diagnosed in four patients (20%) and with A/
Sydney/05/97-like H3N2 in three patients (15%). No seroconversion to
influenza B viruses, adenovirus or respiratory syncytial virus was
obtained. In addition, serological tests were negative for measles, dengue
and rubella.
The percentages of notified cases during the outbreak by age group
were 28.4%, 29.0%, 20.7%, 6.2% and 15.7% for 0-4, 5-9,10-14, 15-19
and older than 20 year subjects, respectively (Table 1). The highest
percentage was observed among children younger than 14 years.
DISCUSSSION
In the present study a higher proportion of notified cases was observed
among teenagers living in the urban area of the county where there is
only one public school. According to public health authorities, the
outbreak was restricted to the urban area. The only case in the 50-60
year old age group was a 52 year old woman who had not been vaccinated,
and no cases among people older than 65 years were notified. Laboratory
confirmation of influenza infection during the acute respiratory illness
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in Iporanga was obtained by both virus isolation and serologic tests.
This investigation demonstrated high seroconversion titers for influenza
virus of subtype H1. The high seroconversion titers to the homologous
influenza virus strains A/Bayern/07/95-like H1N1 and the lack of
antibody response to the influenza virus strain A/Beijing/262/95-like
H1N1 agree with DAVENPORT et al.4 who demonstrated that the sera
of children contain antibodies of limited scope essentially oriented toward
the dominant antigens of the strains recently prevailing. The results from
that study supported the theory that during the initial infections with
influenza viruses, which occur predominantly in childhood, the major
antigens of the prevailing strains have a unique effect upon the antibody
forming mechanisms which persists throughout life and largely
determines the character of the future antibody with which this cohort
of the population will respond when subsequently exposed to related
virus strains.
The high seroconversion titers against the influenza virus strains A/
Taiwan/01/86-like H1N1 was probably due to the circulation of these
strains in the Southeastern region of Brazil during 1996. The higher
incidence of subtype (H1N1) during the influenza season, of 1996, when
compared to previous years, was observed worldwide18.
The only seroconversion titer for the three different H1N1 strains
was obtained from a serum sample collected from a 10 year old child,
and the titers were 40-320, < 10-320 and < 10-40 for the A/Taiwan/01/
86, A/Bayern/07/95 and A/Beijing/262/95 influenza virus strains,
respectively. It was also observed that the high seroconversion titers to
A/Taiwan/01/86-like H1N1 did not protect the children against influenza
virus strain A/Bayern/07/95, due to the fact that this strain was
antigenically distinguishable from the reference strains A/Taiwan/1/86
and A/Texas/36/91 (H1N1) which were circulating worldwide and an
H1 vaccine component was included in the 1997-98 season33.
In addition, the mixed infection obtained between influenza virus
H1 and H3 subtypes was also demonstrated. Since these subtypes have
been cocirculating worldwide since 1977 as reported by KUNG et al.12,
the results of this study also suggest that during an epidemic natural
infections with both subtypes may occur. The incidence of mixed
infection by both influenza A subtypes has already been described5,10,36,37.
FRANK et al.6, in 1983, demonstrated that individuals may be infected
with two subtypes of influenza A virus during the same season, and
found that this incidence was 12% in school children during the 1980-
1981 influenza season, in the Houston Family Study, during a period of
two mixed outbreak due to two subtypes of influenza A virus (H3N2
and H1N1). On the other hand, the antibody titer to A/Wuhan/359/95-
like H3N2 (95%) and A/Sydney/05/97-like H3N2 (80%) detected in
paired sera may be due to cross-reaction with previous related strains.
According to SMITH & DAVIES24, the HI antibody produced in response
to infection with one strain of the H3N2 series often cross-reacted with
subsequent variants. Regarding influenza B viruses, low antibody levels
against influenza B/Beijing/184/93 were detected in 15% of the studied
samples.
Influenza virus incidence is generally high among children and young
adults, but serious complications are much more likely to occur among
the very young (<1 year of age) and the elderly (those over 65)14,25,27.
Studies from the 1950s and early 1960s have suggested that school age
children are the most important source of the spread of virus within
communities3,23. Similarly, as demonstrated in previous studies3,23,28,
Table 1
Age distribution of acute respiratory illness cases in Iporanga*
Age group Population % Number
(years) of cases
0-4 569 28.4 92
5-9 593 29.0 94
10-14 587 20.7 67
15-19 545 6.2 20
20-49 2488 15.7 51
Total 4782 100.0 324
* Data obtained from June to July, 1999.
Provided by the DIR XVII Registro - D.V.E.
Fig.1 -  Distribution of acute respiratory illness cases in Iporanga, by day,  during June-July 1999.
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school age children introduce the infection into their families. In addition,
pre-school age children also have an important role in producing
community spread of influenza virus, presumably through casual and
organized play activities8,15. Despite a high frequency of influenza in
children and young adults, few people in these age groups have
complications or require hospitalization (approximately 6 per 10,000
individuals in the age group of 5 to 24 years)22. The higher hospitalization
rate occurs in the very young (under one year old) and in the elderly2,9
with rates estimated at 50 and 30 to 38 per 10,000, respectively22.
Pneumonia is the major cause of hospitalization in the elderly.
Independent of the age of the patient, chronic conditions such as
cardiovascular disease, pulmonary disease, diabetes mellitus and asthma
can considerably increase the probability of severe or complicated
influenza, requiring hospitalization, and increase the death rate by
approximately 40–fold. Combined pulmonary and cardiovascular disease
can increase the risk of death by 800-fold1.
Influenza A/Bayern/07/95 circulated in the United States between
October 1995 and February 1996 and 50% of the viruses isolated in
South America between April and October 1996 were closely related to
A/Bayern/07/95. Influenza virus related to A/Bayern/07/95 was first
isolated in Brazil in June 1996 in the city of Curitiba and in July 1996 in
the city of São Paulo, in the South and Southeast regions of Brazil,
respectively. This virus was the only subtype H1N1 influenza virus
detected in 1997 in the Southeastern region of Brazil. During the influenza
season of 1998, it was detected only in São José do Rio Preto. So far,
this strain has been detected only in the Southern and Southeastern
regions of Brazil18.
In early April 1999 about 9 million doses of influenza vaccine were
administered to elderly people in Brazil30. The vaccination campaign among
people older than 65 living in Iporanga reached 72.4% of the target
population, suggesting significant protection against A/Bayern/7/95, which
is antigenically and genetically related to A/Beijing/262/95, a component
of the 1999 vaccine. Vaccines containing A/Beijing/262/95 (H1N1)
stimulated postimmunization HI antibodies which were equivalent in
frequency and titre to both A/Beijing/262/95-like and A/Bayern/7/95-like
viruses34. The effectiveness of influenza vaccine depends primarily on the
age and immunocompetence of vaccine recipients and the degree of
similarity between the virus strains in the vaccine and those in circulation,
as demonstrated in this investigation by both virus isolation and
characterization. When an antigenic match occurs between vaccine and
the predominant circulating strains, approximately 70-90% of vaccinated
healthy persons younger than 65 years are protected19. Among elderly
persons living outside nursing homes or similar chronic-care facilities,
influenza vaccine is 30-70% effective in preventing hospitalization for
pneumonia and influenza16,17. For those persons residing in nursing homes,
influenza vaccine is most effective in preventing severe illness, secondary
complications, and deaths. Consequently, in this population the vaccine
can be 50-60% effective in preventing hospitalization or pneumonia and
80% effective in preventing death, even though the effectiveness in
preventing influenza illness often ranges from 30% to 40%21. This
investigation also suggests vaccination strategies for the elderly who are
at increased risk for complications from influenza.
This fact emphasizes the importance of maintenance of active
surveillance of influenza circulation, so that a more adequate vaccine
composition can be selected for each year.
RESUMO
Epidemia de influenza A (H1N1) no Município de Iporanga,
SP, Brasil
 Durante os meses de junho e julho de 1999, foram notificados 324
casos de doença respiratória aguda no Município de Iporanga-SP. O
isolamento do vírus da influenza do tipo A/Bayern/07/95 (H1N1) e a
conversão sorológica para a estirpe viral (H1N1) foram de 57,1% e 100%,
respectivamente. A porcentagem de casos com diagnóstico clínico
notificados durante a epidemia foi de 28,4%, 29,0%, 20,7%, 6,2% e
15,7%, nas faixas etárias de 0-4, 5-9, 10-14, 15-19 anos e indivíduos
acima de 20 anos de idade, respectivamente. Observou-se maior
incidência da doença entre os indivíduos menores de 14 anos. Atribui-se
a ausência de notificação de casos em indivíduos maiores de 65 anos à
campanha de vacinação, na população idosa de Iporanga, que em 1999
atingiu 72,4%. O virus isolado é genética e antigenicamente semelhante
à estirpe A/Beijing/262/95 (H1N1), o componente H1 da vacina de 1999.
Vacinas contendo a estirpe A/Beijing/262/95 (H1N1) estimularam, após
imunização, anticorpos inibidores da hemaglutinação, os quais foram
equivalentes em freqüência e título para ambas as estirpes: A/Bayern/
07/95 e A/Beijing/262/95.
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